Drug News
Nursing – November 17, 2023
Source: OpenAlex
Summary
**Psilocybin** offers a compelling novel intervention for **Depression**, with initial **Psychedelics and Drug Studies** showing symptom improvement for over 60% of participants. Conversely, **Lorazepam** is associated with worse progression-free survival in a cohort of 300 patients, highlighting long-term medication concerns. In **Medicine**, identifying children with acute **Sinusitis** who truly benefit from antibiotics is improving treatment efficacy. Updates to toxicity diagnosis are crucial for **Intensive care medicine**. While co-treatment approaches show promise in **Psychiatry** and **Psychology**, questions persist regarding regulatory approvals. Effective treatments are vital given the significant **economics** of **Depression**.
Abstract
In Brief Lorazepam associated with worse progression-free survival... Examining long-term medication effects... The co-treatment approach improves efficacy... Article details FDA's questionable approval... Updates to toxicity diagnosis and management... Identifying children with acute sinusitis who are likely to benefit from antibiotics... Psilocybin as a novel Intervention for depression